236 related articles for article (PubMed ID: 11433342)
1. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease.
Fontaine P; Roy-Proulx G; Knafo L; Baron C; Roy DC; Perreault C
Nat Med; 2001 Jul; 7(7):789-94. PubMed ID: 11433342
[TBL] [Abstract][Full Text] [Related]
2. Adoptive cancer immunotherapy: discovering the best targets.
Perreault C; Brochu S
J Mol Med (Berl); 2002 Apr; 80(4):212-8. PubMed ID: 11976730
[TBL] [Abstract][Full Text] [Related]
3. Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease.
Perreault C; Jutras J; Roy DC; Filep JG; Brochu S
J Clin Invest; 1996 Aug; 98(3):622-8. PubMed ID: 8698852
[TBL] [Abstract][Full Text] [Related]
4. T cells targeted against a single minor histocompatibility antigen can cure solid tumors.
Meunier MC; Delisle JS; Bergeron J; Rineau V; Baron C; Perreault C
Nat Med; 2005 Nov; 11(11):1222-9. PubMed ID: 16227989
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-host disease associated T helper cell responses specific for minor histocompatibility antigens are mainly restricted by HLA-DR molecules.
van Els CA; Zantvoort E; Jacobs N; Bakker A; van Rood JJ; Goulmy E
Bone Marrow Transplant; 1990 Jun; 5(6):365-72. PubMed ID: 2142441
[TBL] [Abstract][Full Text] [Related]
6. Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy.
Pion S; Fontaine P; Baron C; Gyger M; Perreault C
J Clin Invest; 1995 Apr; 95(4):1561-8. PubMed ID: 7706462
[TBL] [Abstract][Full Text] [Related]
7. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of cancer through targeting of minor histocompatibility antigens.
Hambach L; Goulmy E
Curr Opin Immunol; 2005 Apr; 17(2):202-10. PubMed ID: 15766682
[TBL] [Abstract][Full Text] [Related]
9. Minors come of age: Minor histocompatibility antigens and graft-versus-host disease.
Chao NJ
Biol Blood Marrow Transplant; 2004 Apr; 10(4):215-23. PubMed ID: 15077220
[TBL] [Abstract][Full Text] [Related]
10. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
[TBL] [Abstract][Full Text] [Related]
11. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
[TBL] [Abstract][Full Text] [Related]
12. Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease.
Spaapen R; Mutis T
Best Pract Res Clin Haematol; 2008 Sep; 21(3):543-57. PubMed ID: 18790454
[TBL] [Abstract][Full Text] [Related]
13. Analysis of immunodominance among minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation.
Mori S; El-Baki H; Mullen CA
Bone Marrow Transplant; 2003 May; 31(10):865-75. PubMed ID: 12748663
[TBL] [Abstract][Full Text] [Related]
14. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia.
Falkenburg JH; Willemze R
Best Pract Res Clin Haematol; 2004 Sep; 17(3):415-25. PubMed ID: 15498713
[TBL] [Abstract][Full Text] [Related]
15. Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application.
Griffioen M; van Egmond HM; Barnby-Porritt H; van der Hoorn MA; Hagedoorn RS; Kester MG; Schwabe N; Willemze R; Falkenburg JH; Heemskerk MH
Haematologica; 2008 Oct; 93(10):1535-43. PubMed ID: 18768532
[TBL] [Abstract][Full Text] [Related]
16. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
17. [Allorecognition of the recipient after hematopoietic transplantation].
Tiberghien P; Robinet E; Ferrand C; Saas P; Hervé P
Bull Cancer; 2003; 90(8-9):706-10. PubMed ID: 14609760
[TBL] [Abstract][Full Text] [Related]
18. Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens.
Friedman TM; Jones SC; Statton D; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2004 Apr; 10(4):224-35. PubMed ID: 15077221
[TBL] [Abstract][Full Text] [Related]
19. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens.
Dickinson AM; Wang XN; Sviland L; Vyth-Dreese FA; Jackson GH; Schumacher TN; Haanen JB; Mutis T; Goulmy E
Nat Med; 2002 Apr; 8(4):410-4. PubMed ID: 11927949
[TBL] [Abstract][Full Text] [Related]
20. Expansion and activation of minor histocompatibility antigen HY-specific T cells associated with graft-versus-leukemia response.
Takami A; Sugimori C; Feng X; Yachie A; Kondo Y; Nishimura R; Kuzushima K; Kotani T; Asakura H; Shiobara S; Nakao S
Bone Marrow Transplant; 2004 Oct; 34(8):703-9. PubMed ID: 15322566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
